104210 Federal Register / Vol. 89, No. 245 / Friday, December 20, 2024 / Notices 

Consortium, Inc. (‘‘Subcutaneous Drug 

Development & Delivery Consortium, 

Inc.’’) has filed written notifications 

simultaneously with the Attorney 

General and the Federal Trade 

Commission disclosing changes in its 

membership. The notifications were 

filed for the purpose of extending the 

Act’s provisions limiting the recovery of 

antitrust plaintiffs to actual damages 

under specified circumstances. 

Specifically, Janssen Research & 

Development, LLC, Malver, PA; Novo 

Nordisk, Bagsvaerd, DENMARK; and 

Ypsomed AG, Burgdorf, 

SWITZERLAND have been added as 

parties to this venture. 

No other changes have been made in 

either the membership or planned 

activity of the group research project. 

Membership in this group research 

project remains open, and Subcutaneous 

Drug Development & Delivery 

Consortium, Inc. intends to file 

additional written notifications 

disclosing all changes in membership. 

On October 26, 2020, Subcutaneous 

Drug Development & Delivery 

Consortium, Inc. filed its original 

notification pursuant to section 6(a) of 

the Act. The Department of Justice 

published a notice in the Federal 

Register pursuant to section 6(b) of the 

Act on December 3, 2020 (85 FR 78148). 

The last notification was filed with 

the Department on April 25, 2024. A 

notice was published in the Federal 

Register pursuant to section 6(b) of the 

Act on September 12, 2024 (89 FR 

74288). 

Suzanne Morris, 

Deputy Director Civil Enforcement 

Operations, Antitrust Division. 

[FR Doc. 2024–30418 Filed 12–19–24; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF JUSTICE 

Antitrust Division 

Notice Pursuant to the National 

Cooperative Research and Production 

Act of 1993—Senior Healthcare 

Innovation Consortium 

Notice is hereby given that, on 

October 2, 2024 pursuant to section 6(a) 

of the National Cooperative Research 

and Production Act of 1993, 15 U.S.C. 

4301 et seq. (‘‘the Act’’), Senior 

Healthcare Innovation Consortium 

(SHIC) has filed written notifications 

simultaneously with the Attorney 

General and the Federal Trade 

Commission disclosing changes in its 

membership. The notifications were 

filed for the purpose of extending the 

Act’s provisions limiting the recovery of 

antitrust plaintiffs to actual damages 

under specified circumstances. 

Specifically, AIVOT Robotics, Inc., 

Seattle, WA; Living Solutions, Afton, 

WY; Thrive360AI, San Francisco, CA; 

and Tornado Therapeutics, Boston, MA, 

have been added as parties to this 

venture. 

No other changes have been made in 

either the membership or planned 

activity of the group research project. 

Membership in this group research 

project remains open, and SHIC intends 

to file additional written notifications 

disclosing all changes in membership. 

On November 2, 2022, SHIC filed its 

original notification pursuant to section 

6(a) of the Act. The Department of 

Justice published a notice in the Federal 

Register pursuant to section 6(b) of the 

Act on November 23, 2022 (87 FR 

71677). 

The last notification was filed with 

the Department on July 10, 2024. A 

notice was published in the Federal 

Register pursuant to section 6(b) of the 

Act on September 26, 2024 (89 FR 

78902). 

Suzanne Morris, 

Deputy Director Civil Enforcement 

Operations, Antitrust Division. 

[FR Doc. 2024–30405 Filed 12–19–24; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF JUSTICE 

Antitrust Division 

Notice Pursuant to the National 

Cooperative Research and Production 

Act of 1993—Medical Technology 

Enterprise Consortium 

Notice is hereby given that, on 

October 7, 2024, pursuant to section 6(a) 

of the National Cooperative Research 

and Production Act of 1993, 15 U.S.C. 

4301 et seq. (‘‘the Act’’), Medical 

Technology Enterprise Consortium 

(‘‘MTEC’’) has filed written notifications 

simultaneously with the Attorney 

General and the Federal Trade 

Commission disclosing changes in its 

membership. The notifications were 

filed for the purpose of extending the 

Act’s provisions limiting the recovery of 

antitrust plaintiffs to actual damages 

under specified circumstances. 

Specifically, Artery Studios, Inc., 

Toronto, CANADA; Astek Diagnostics, 

Inc., Halethorpe, MD; BBC 

Entrepreneurial Training and 

Consulting, LLC, Chelsea, MI; Bluestaq, 

LLC, Colorado Springs, CO; Carrtech 

Corp., Dickerson, MD; Concept Plus, 

LLC, Fairfax, VA; Crescel, LLC, Miami 

Beach, FL; Culmen International, LLC, 

Alexandria, VA; DeployX Services, Inc., 

McLean, VA; Digital For Mental Health, 

Paris, FRANCE; Emvision Medical 

Devices, Ltd., Macquarie Park, 

AUSTRALIA; Galapagos Federal 

Systems, LLC, Kihei, HI; GoDx, Inc., 

Madison, WI; Government Acquisitions, 

Inc., Cincinnati, OH; IntelliDyne, LLC, 

Vienna, VA; IRegained, Inc., Sudbury, 

CANADA; Northeastern University, 

Boston, MA; Nytricx, Inc., Athens, GA; 

Omnix Medical, Jerusalem, ISRAEL; 

Perfusio Corp., Greenville, NC; 

Protondx, Ltd., London, UNITED 

KINGDOM; PSC Biotech Corp., Pomona, 

CA; Razom, Inc., New York, NY; ReliOx 

Corp., Jacksonville, FL; SeaStar Medical, 

Inc., Denver, CO; SPEAR Human 

Performance, Inc., Tallahassee, FL; 

SPOC Proteomics, Inc., Scottsdale, AZ; 

TechWerks, LLC, Arlington Heights, IL; 

The Neutrino Donut, LLC, Culver City, 

CA; Unify Medical, Cleveland, OH; 

University of South Carolina, Columbia, 

SC; Wearabledose, Inc., Bowie, MD; 

Zeteo Tech, Inc., Sykesville, MD; and 

ZuluCare, LLC, Bethpage, NY, have 

been added as parties to this venture. 

No other changes have been made in 

either the membership or planned 

activity of the group research project. 

Membership in this group research 

project remains open, and MTEC 

intends to file additional written 

notifications disclosing all changes in 

membership. 

On May 9, 2014, MTEC filed its 

original notification pursuant to section 

6(a) of the Act. The Department of 

Justice published a notice in the Federal 

Register pursuant to section 6(b) of the 

Act on June 9, 2014 (79 FR 32999). 

The last notification was filed with 

the Department on June 28, 2024. A 

notice was published in the Federal 

Register pursuant to section 6(b) of the 

Act on September 16, 2024 (89 FR 

75566). 

Suzanne Morris, 

Deputy Director Civil Enforcement 

Operations, Antitrust Division. 

[FR Doc. 2024–30411 Filed 12–19–24; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF JUSTICE 

Antitrust Division 

Notice Pursuant to the National 

Cooperative Research and Production 

Act of 1993—Naval Surface 

Technology & Innovation Consortium 

Notice is hereby given that, on 

October 10, 2024, pursuant to section 

6(a) of the National Cooperative 

Research and Production Act of 1993, 

15 U.S.C. 4301 et seq. (‘‘the Act’’), Naval 

Surface Technology & Innovation 


ddrumheller on DSK120RN23PROD with NOTICES1